Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Health-related Research Ethics and Social Value: Antibiotic Resistance Intervention Research and Pragmatic Risks
Univ Gothenburg, Dept Philosophy Linguist & Theory Sci, Box 200, SE-40530 Gothenburg, Sweden. unthe, Christian; Nijsingh, Niels; Larsson, D. G. Joakim.ORCID iD: 0000-0003-0761-960X
KTH.
2019 (English)In: Bioethics, ISSN 0269-9702, E-ISSN 1467-8519, Vol. 33, no 3, p. 335-342Article in journal (Refereed) Published
Abstract [en]

We consider the implications for the ethical evaluation of research programs of two fundamental changes in the revised research ethical guideline of the Council for International Organizations of Medical Sciences. The first is the extension of scope that follows from exchanging "biomedical" for "health-related" research, and the second is the new evaluative basis of "social value," which implies new ethical requirements of research. We use the example of antibiotic resistance interventions to explore the need to consider the instances of what we term the pragmatic risks of such interventions to evaluate the social value of certain kinds of health-related research. These (pragmatic) risks severely threaten the social value of interventions in every area where human and social responses significantly impact on their effectiveness. Thus, the social value of health-related research needed to demonstrate its effectiveness depends on the extent and successful management of such risks. Research designed to take into account the management of pragmatic risks also gives rise to similar types of risks, and the potential for social value in light of those risks needs to be considered in ethical reviews based on the new guidelines. We argue that, to handle this new expanded task, the international system of research ethical review addressed by the guidelines needs institutional development.

Place, publisher, year, edition, pages
Wiley , 2019. Vol. 33, no 3, p. 335-342
Keywords [en]
antimicrobial resistance, CIOMS, drug resistance, evidence-based practice, health policy, research ethics
National Category
Ethics
Identifiers
URN: urn:nbn:se:kth:diva-248353DOI: 10.1111/bioe.12580ISI: 000461876800005PubMedID: 30884548Scopus ID: 2-s2.0-85063303607OAI: oai:DiVA.org:kth-248353DiVA, id: diva2:1302719
Note

QC 20190405

Available from: 2019-04-05 Created: 2019-04-05 Last updated: 2019-04-05Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Munthe, ChristianDe Fine Licht, Karl
By organisation
KTH
In the same journal
Bioethics
Ethics

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 32 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf